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STAT3, a member of the Signal Transducers and Activators of Transcription (STAT) 
family, is constitutively activated by phosphorylation on tyrosine 705 in a high percentage of 
tumors and tumor-derived cell lines of both liquid and solid origin, downstream of cytokines, 
growth factors and oncogenes1. Tumor cells often become addicted to STAT3, as shown by 
the observation that interference with its transcriptional activity often triggers growth arrest 
and/or cell death. Importantly, STAT3 can also be phosphorylated on Serine 727 downstream 
of a number of stimuli leading to the activation of MAP kinases including RAS signaling2. 
Although STAT3-mediated gene expression signature is mostly consistent with tumor cell 
survival and proliferation3, it varies in different tumor types, and a core activity determining 
addiction to STAT3 by a wide spectrum of biologically distinct tumors has not yet been 
identified.  
To address this point, we have generated knock-in mice expressing physiological 
levels of the constitutively active STAT3C mutant form. Stat3C cooperates with the rat Neu 
oncogene triggering the production of more invasive mammary tumors via up-regulation of 
the focal adhesion protein CTEN4. In order to dissect the molecular functions of 
constitutively activated STAT3, we have analyzed primary mouse embryonic fibroblasts 
(MEF) derived from STAT3C/C or STAT3WT/WT mice5. STAT3C/C MEFs showed increased 
proliferation, protection from apoptotic stimuli, decreased production of Reactive Oxygen 
Species (ROS) and delayed physiological senescence. Intriguingly, gene expression profiling 
revealed that STAT3C/C cells down-regulated nuclear-transcribed mitochondrial genes, 
including many encoding for proteins belonging to the Electron Transport Chain (ETC) 
complexes, and up-regulated mRNAs involved in glycolysis, first of all Hypoxia Inducible 
Factor (HIF)-1α.  
Recently, STAT3 was shown to play an unconventional role in mitochondria6-8. 
Mitochondrial STAT3 (mSTAT3) appears to sustain ETC basal activity under normal or 
RAS-transformed conditions, supporting RAS-dependent oncogenic transformation6,7, and it 
was suggested to act as a negative regulator of the Mitochondrial Permeability Transition 
Pore (MPTP), thus mediating cardioprotection after ischemia/reperfusion8. Ser727 is required 
for mSTAT3 functions, but not Tyr705, nuclear localization or DNA binding activity. Indeed, 
activated RAS triggers Ser-phosphorylation rather than the conventional phosphorylation on 
Tyr, which in contrast confers nuclear localization and transcriptional activity and drives 
nuclear (n) STAT3 functions3. STAT3C mitochondrial localization was normal and mSTAT3 
activities appeared to be preserved in the STAT3C/C cells5. Nevertheless, mitochondrial 
activity and ATP production were reduced and could not be rescued by HIF-1α silencing. 
Moreover, preliminary data suggest that the defective expression of several ETC proteins can 
be rescued upon STAT3 silencing (VP and M. Wieckowski, unpublished data), supporting 
the idea that the action of constitutively activated STAT3 on mitochondria is dominant and 
occurs primarily in the nucleus via direct or indirect transcriptional down-regulation of 
mitochondrial genes. Always in the nucleus, the constitutively activated STAT3 up-regulates 
transcription of the HIF-1α gene, leading to HIF-1α-mediated up-regulation of glycolysis 
including high glucose consumption and strong dependence on glucose for survival.  
Thus, activated STAT3 acts as a master regulator of the metabolic switch from 
mitochondrial respiration to glycolysis occurring in most cancer cells and known as the 
‘Warburg Effect”9, by promoting HIF-1α-dependent aerobic glycolysis while depressing 
mitochondrial activity in a HIF-1α-independent fashion. This switch is an important 
component of STAT3 pro-oncogenic activities, since inhibition of STAT3 tyrosine 
phosphorylation and dimerization via the small molecule inhibitor S3I in several STAT3-
dependent tumor cell lines down-regulates glycolysis and enhances mitochondrial activity 
prior to leading to growth arrest and cell death, both in vitro and in vivo5. Moreover, primary 
STAT3C/C MEFs become transformed and tumorigenic when immortalized via the 3T3 
protocol, suggesting that constitutively active STAT3 can provide a first hit in the multi-step 
transformation process (MD et al., manuscript in preparation).  
 As depicted in Figure 1, at least two functionally distinct STAT3s exist: nSTAT3, 
acting in a conventional way to regulate gene transcription as a Tyr-phosphorylated dimer, 
and mSTAT3, which acts unconventionally to regulate mitochondrial functions, presumably 
requiring phosphorylation on Ser727. mSTAT3 preserves ETC activity both under basal and 
RAS-transformed conditions, and may provide protection from apoptosis upon stresses such 
as ischemia/reperfusion by regulating MPTP opening6-8. Our data suggest that nSTAT3, 
when constitutively transcriptionally activated as it occurs downstream of oncogenic and 
inflammatory signals that trigger its tyrosine phosphorylation, promotes aerobic glycolysis 
and lowers cellular respiration, resulting in enhanced proliferation, resistance to hypoxia, 
glucose dependence and, importantly, decreased ROS production and resistance to apoptosis 
and senescence. Thus, although regulated downstream of different signals under distinct 
physiological or pathological conditions, nSTAT3 and mSTAT3 finally converge to enhance 
cell survival and protection from apoptosis via specific regulation of mitochondrial functions. 
Among other outstanding issues, it will be important to assess if and how the altered relative 
levels of Tyr-phosphorylated or Ser-phosphorylated STAT3 brought about by different 
oncogenic signals and inflammatory/stress conditions, altering the balance between nuclear 
and mitochondrial STAT3, can lead to an altered metabolic output. 
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FIGURE LEGEND 
Figure 1. Converging roles of nuclear (n) and mitochondrial (m) STAT3. Different signals 
can selectively trigger STAT3 phosphorylation. Tyr-phosphorylated nSTAT3 (P-Y) 
mediates, among others, the up-regulation of HIF-1α transcription and the down-regulation of 
mitochondrial genes, thus triggering faster proliferation10, decreased ROS production and 
resistance to apoptosis. On the other end, Ser-phosphorylated mSTAT3 (P-S) preserves ETC 
activity and regulates MPTP opening, ultimately also leading to apoptosis protection. 
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